Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
    Meeting Abstract

    Jones, R. L.; Blay, J. Y.; Agulnik, M.; Chugh, R.; Mir, O.; Italiano, A.; Thomas, D.; Gupta, A.; Jahan, T.; Cote, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Kelley, R. K.; El-Khoueiry, A. B.; Meyer, T.; Rimassa, L.; Merle, P.; Chan, S. L.; Tran, A.; Parnis, F.; Tam, V. C.; Cattan, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
    Meeting Abstract

    Lacouture, M.; Dion, H.; Ravipaty, S.; Akmaev, V. R.; Sarangarajan, R.; Jimenez, J. J.; Narain, N. R.; Berman, B.; Goldfarb, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer
    Meeting Abstract

    Leboulleux, S.; Lee, E. K.; Bastholt, L.; Tahara, M.; Wirth, L. J.; Sherman, S. I.; Robinson, B. G.; Teng, A.; Joshi, P.; Misir, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Dairiki, R.; Sachdev, P.; Dutcus, C. E.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
    Meeting Abstract

    Galsky, M. D.; Banchereau, R.; Kadel, E. E. 3rd; Ramirez-Montagut, T.; Mariathasan, S.; Thåström, A.; Rosenberg, J.; Powles, T.; van der Heijden, M. S.; Necchi, A.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
    Meeting Abstract

    George, S.; Heinrich, M.; Chi, P.; Razak, A.; von Mehren, M.; Gordon, M.; Ganjoo, K. N.; Somaiah, N.; Trent, J. C.; Rodon Ahnert, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
    Meeting Abstract

    Hecht, J. R.; Naing, A.; Falchook, G. S.; Patel, M. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Javle, M.; Bendell, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems
    Meeting Abstract

    Hornberger, J.; Graf, R. P.; Hulling, M.; Attard, G.; Allan, A.; Dittamore, R.; Scher, H. I.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naive prostate cancer (HSPC)
    Meeting Abstract

    Harrison, M. R.; Davis, P. G.; Khouri, M. G.; Gupta, R. T.; Armstrong, A. J.; McNamara, M. A.; Zhang, T.; Anand, M.; Onyenwoke, K.; Hood, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save